Brensocatib
- Generic Name
- Brensocatib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24N4O4
- CAS Number
- 1802148-05-5
- Unique Ingredient Identifier
- 25CG88L0BB
- Background
Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).
- Indication
用于非囊性纤维化支气管扩张症（NCFBE）成人患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 204
- Registration Number
- NCT06685835
- Locations
- 🇺🇸
USA004, Tampa, Florida, United States
🇺🇸USA003, Plainfield, Indiana, United States
🇺🇸USA016, Springfield, Ohio, United States
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase 2
Recruiting
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 270
- Registration Number
- NCT06013241
- Locations
- 🇺🇸
USA034, Tucson, Arizona, United States
🇺🇸USA002, Roseville, California, United States
🇺🇸USA006, Upland, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath